This method could usher in a new approach to delivery of drugs in general
Freiburg researchers find purely chemical way to target therapeutic nano-containers to cells
Scientists have discovered that a polymer can provide a key to get into tumors: Prof. Prasad Shastri, Director of the Institute of Macromolecular Chemistry and core member of the cluster of excellence BIOSS Centre for Biological Signalling Studies at the University of Freiburg, and graduate students Julia Voigt and Jon Christensen have developed a new paradigm to home nanoparticles, containers that measure a few 100 nanometers in size, to endothelial cells. Using just charged polymers with the right affinity for cell lipids the team has developed nanoparticles that can recognize specific cell types simply by their chemical properties. “This is a remarkable discovery, as it allows for the first time to target a specific cell type purely through biophysical principles, and without using the traditional ligand-receptor approach” says Prof. Shastri who led the study that was selected as cover article of the Proceedings of the National Academy of Sciences. Until now researchers placed molecules on nanoparticles that can latch onto proteins on cell surface – called receptors.
These receptors act as an address or a biological postal code. However in tumors these addresses can change rapidly with time. To solve this lack of precision Shastri and team developed particles that are delivered to endothelial cells using a biophysical approach. “This delivery approach does not require a biological postal code for targeting of nanoparticles and is an important step forward in developing nanoparticle based systems for treating cancers” says Julia Voigt the lead author of the paper.
Cancers are very hungry tissues and they need constant nourishment. This is provided through their own supply of blood vessels. “By going after endothelial cells that make up these blood vessels, we can starve the tumor or kill it with one payload” says Jon Christensen who is a co-author on this study and works on tumor metastasis.
Nanoparticles are used to deliver therapeutics in treating cancers. These very small pills, cornerstones of nanomedicine, get injected into the body and reach the tumor cells via the bloodstream. When they find the targeted cells, they need to be eaten so that the drug can act within the cell.
The Latest on: Nanomedicine
via Google News
The Latest on: Nanomedicine
- Nanomedicine Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027on November 26, 2020 at 11:16 am
The research report on Nanomedicine provide insights on growth-influencing factors such as industry trends, understanding consumer demands, product application, competitive landscape, pricing analysis ...
- Nanomedicine Market Futuristic Comprehensive Insights Report [Forecast 2029] | Abbott Laboratories, Ablynx NVon November 24, 2020 at 10:12 pm
Nov 24, 2020 (WiredRelease via Comtex) -- A consciously conceived and designed business intelligence report titled Global Nanomedicine market 2020 by Manufacturers, Type, and Application ...
- Delivering Nanomedicine to Solid Tumorson November 24, 2020 at 4:00 pm
For optimal efficacy, a therapeutic agent must reach tumors in amounts sufficient to kill cancer cells but at the same time should not have adverse effects in normal tissues. Obviously, the ...
- Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivityon November 21, 2020 at 4:00 pm
19 Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. 20 Center for Nanomedicine and Department of Molecular, Cellular, and Developmental Biology, ...
- NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United Stateson November 21, 2020 at 7:28 am
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the “ Company ”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it ...
- NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United Stateson November 20, 2020 at 11:03 am
About NANOBIOTIX Nanobiotix is a French, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
- NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United Stateson November 20, 2020 at 10:24 am
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer ...
- CRISPR/Cas9 system is highly effective in treating metastatic cancerson November 18, 2020 at 11:11 pm
Dan Peer, VP for R&D and Head of the Laboratory of Precision Nanomedicine at the Shmunis School of Biomedicine and Cancer Research at TAU. The research was conducted by Dr. Daniel Rosenblum ...
- Nanomedicine at the crossroads – Why good chemistry is not enoughon November 18, 2020 at 6:00 am
Nowadays, an emerging number of advanced therapies conquer the global market. Nanotechnology-related drug products show groundbreaking opportunities in cancer therapy. Still the translation of ...
- TOTTENHAM ACQUISITION I LIMITEDon November 18, 2020 at 2:09 am
About Clene Nanomedicine, Inc. Clene Nanomedicine, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the development of unique therapeutic candidates for ...
via Bing News